These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 38068988)

  • 41. [Evaluation of anticoagulant activity for low molecular-weight heparin by chromogenic substrate. Measurement of factor Xa and thrombin activities].
    Ishimitsu S; Sugiyama T; Itoh M; Natsuga T; Komatsu H; Okada S
    Yakugaku Zasshi; 1994 Aug; 114(8):611-7. PubMed ID: 7932105
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Effect of unfractionated and low-molecular-weight heparin on platelet aggregation and in vitro bleeding time in dogs].
    Nimmerfall K; Mischke R
    Dtsch Tierarztl Wochenschr; 1999 Oct; 106(10):439-44. PubMed ID: 10589154
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antithrombin binding of low molecular weight heparins and inhibition of factor Xa.
    Lin P; Sinha U; Betz A
    Biochim Biophys Acta; 2001 Apr; 1526(1):105-13. PubMed ID: 11287128
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison of reversal activity and mechanism of action of UHRA, andexanet, and PER977 on heparin and oral FXa inhibitors.
    Kalathottukaren MT; Creagh AL; Abbina S; Lu G; Karbarz MJ; Pandey A; Conley PB; Kizhakkedathu JN; Haynes C
    Blood Adv; 2018 Aug; 2(16):2104-2114. PubMed ID: 30135185
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Heparin chain-length dependence of factor Xa inhibition by antithrombin in plasma.
    Rezaie AR
    Thromb Res; 2007; 119(4):481-8. PubMed ID: 16515805
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Monitoring low molecular weight heparins at therapeutic levels: dose-responses of, and correlations and differences between aPTT, anti-factor Xa and thrombin generation assays.
    Thomas O; Lybeck E; Strandberg K; Tynngård N; Schött U
    PLoS One; 2015; 10(1):e0116835. PubMed ID: 25625201
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacological strategies for inhibition of thrombin activity.
    Alban S
    Curr Pharm Des; 2008; 14(12):1152-75. PubMed ID: 18473863
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Histidine-rich glycoprotein binds factor XIIa with high affinity and inhibits contact-initiated coagulation.
    MacQuarrie JL; Stafford AR; Yau JW; Leslie BA; Vu TT; Fredenburgh JC; Weitz JI
    Blood; 2011 Apr; 117(15):4134-41. PubMed ID: 21304106
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Inhibitory effects of TFPI on thrombin and factor Xa generation in vitro--modulatory action of glycosaminoglycans.
    Kaiser B; Hoppensteadt DA; Jeske W; Wun TC; Fareed J
    Thromb Res; 1994 Sep; 75(6):609-16. PubMed ID: 7831680
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Coagulation inhibition capacities of low-molecular mass and unfractionated heparin, as determined by thrombin generation.
    Elgue G; Sanchez J; Egberg N; Olsson P
    Thromb Res; 1994 Sep; 75(5):539-49. PubMed ID: 7992254
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Anticoagulant activity and pleiotropic effects of heparin.
    Bal Dit Sollier C; Dillinger JG; Drouet L
    J Med Vasc; 2020 May; 45(3):147-157. PubMed ID: 32402428
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Monitoring therapeutic anticoagulation with low molecular weight heparins: is it useful or misleading?
    Hammerstingl C
    Cardiovasc Hematol Agents Med Chem; 2008 Oct; 6(4):282-6. PubMed ID: 18855641
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Inhibition of coagulation and platelet adhesion to extracellular matrix by unfractionated heparin and a low molecular weight heparin.
    Krupinski K; Basic-Micic M; Lindhoff E; Breddin HK
    Blut; 1990 Nov; 61(5):289-94. PubMed ID: 2176900
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Histidine-rich glycoprotein modulation of the anticoagulant activity of heparin. Evidence for a mechanism involving competition with both antithrombin and thrombin for heparin binding.
    Peterson CB; Morgan WT; Blackburn MN
    J Biol Chem; 1987 Jun; 262(16):7567-74. PubMed ID: 3584128
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mechanisms for the antithrombotic activity in man of low molecular weight heparins (LMWHs).
    Samama MM; Bara L; Gerotziafas GT
    Haemostasis; 1994; 24(2):105-17. PubMed ID: 7959358
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Low molecular weight heparin-catalyzed inactivation of factor Xa and thrombin by antithrombin III--effect of platelet factor 4.
    Schoen P; Lindhout T; Franssen J; Hemker HC
    Thromb Haemost; 1991 Oct; 66(4):435-41. PubMed ID: 1665594
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ultrasonic-assisted preparation of a low molecular weight heparin (LMWH) with anticoagulant activity.
    Achour O; Bridiau N; Godhbani A; Le Joubioux F; Bordenave Juchereau S; Sannier F; Piot JM; Fruitier Arnaudin I; Maugard T
    Carbohydr Polym; 2013 Sep; 97(2):684-9. PubMed ID: 23911501
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Direct inhibitors of coagulation proteins - the end of the heparin and low-molecular-weight heparin era for anticoagulant therapy?
    Laux V; Perzborn E; Heitmeier S; von Degenfeld G; Dittrich-Wengenroth E; Buchmüller A; Gerdes C; Misselwitz F
    Thromb Haemost; 2009 Nov; 102(5):892-9. PubMed ID: 19888525
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Physiological function of tissue factor pathway inhibitor and interaction with heparins.
    Sandset PM; Bendz B; Hansen JB
    Haemostasis; 2000; 30 Suppl 2():48-56. PubMed ID: 11251341
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins.
    Verstraete M
    Drugs; 1990 Oct; 40(4):498-530. PubMed ID: 1964634
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.